Aaron Logan, MD, PhD

Aaron Logan, MD, PhD, is an associate professor of clinical medicine in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF) School of Medicine, as well as a member of the UCSF Helen Diller Family Comprehensive Cancer Center

Articles

Obe-Cel Data Are Poised to Refine and Expand the ALL Treatment Paradigm: With Aaron Logan, MD, PhD; and Bijal Shah, MD, MS

August 26th 2025

Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm and how the use of this agent might expand going forward.

Reflections and Future Directions in R/R ALL

February 20th 2025

Panelists discuss collaboration strategies for chimeric antigen receptor (CAR) T-cell therapy referral, reflections on advancements in relapsed/refractory acute lymphoblastic leukemia (R/R ALL) throughout 2024, key accomplishments, and future opportunities for progress in 2025.

Outpatient CAR T Therapy and Expanding Access

February 20th 2025

Panelists discuss strategies for managing transitions of care for chimeric antigen receptor (CAR) T-cell therapy patients, including monitoring for long-term toxicities as well as the feasibility and logistics of administering CAR T therapy in the outpatient vs inpatient setting.

Health Care Resource Utilization and Transition of Care

February 20th 2025

Panelists discuss routine laboratory monitoring for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) as well as insights from the American Society of Hematology Annual Meeting and Exposition (ASH 2024) data on health care resource utilization and costs associated with administering chimeric antigen receptor (CAR) T-cell therapy and managing related toxicities.

Addressing Toxicities in CAR T-Cell Therapy

February 13th 2025

Panelists discuss future directions and unmet needs for chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory (R/R) B-cell acute lymphocytic leukemia (ALL) as well as risk factors that may predict higher likelihoods of severe cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in patients undergoing treatment.

Optimizing Bridging Therapies and Post–CAR T Approaches

February 13th 2025

Panelists discuss the impact of blinatumomab’s FDA approval on sequencing chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory acute lymphoblastic leukemia (R/R ALL), the use of bridging therapies prior to CAR T infusion, and approaches to consolidation or maintenance treatment following CAR T therapy.

Shifting Treatment Paradigms in R/R ALL

February 6th 2025

Panelists discuss how minimal residual disease (MRD) outcomes with obecabtagene autoleucel (obe-cel) compare with those with brexucabtagene autoleucel (brexu-cel) and how the FDA approval of obe-cel may impact treatment decisions in relapsed/refractory acute lymphoblastic leukemia (R/R ALL), including considerations for patient factors, such as MRD status, Philadelphia status, and high-risk features.

Obe-Cel and MRD Outcomes: Insights and Comparisons

February 6th 2025

Panelists discuss how real-world outcomes data from the CIBMTR registry on brexucabtagene autoleucel (brexu-cel) presented at the American Society of Hematology Annual Meeting and Exposition (ASH 2024) align with clinical practice, as well as the key findings from the FELIX trial, including minimal residual disease (MRD) outcomes and comparisons with the ZUMA-3 trial for obecabtagene autoleucel (obe-cel) in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Clinical Trials and Real-World Data on Brexu-Cel

January 30th 2025

Panelists discuss how the dosing and lymphodepletion regimens of brexucabtagene autoleucel (brexu-cel), tisagenlecleucel (tisa-cel), and obecabtagene autoleucel (obe-cel) differ, with insights into obe-cel’s double infusion approach, as well as a deeper dive into the ZUMA-3 trial’s design and data updates with brexu-cel in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Introduction to CAR T-Cell Therapies in R/R ALL

January 30th 2025

Panelists discuss how the recent FDA approval of obecabtagene autoleucel (obe-cel) for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) adds to the existing chimeric antigen receptor (CAR) T-cell therapies, with a focus on the differences in their mechanisms, structures, and FDA indications.

Dr. Logan Discusses Acalabrutinib in CLL

March 19th 2018

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses acalabrutinib (Calquence) in chronic lymphocytic leukemia.

Dr. Logan Discusses Ibrutinib Plus Venetoclax in CLL

March 2nd 2018

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in chronic lymphocytic leukemia.

Dr. Logan Discusses Treatment Options in CLL

December 19th 2017

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia.